Abstract
Amgen Inc and Kirin Brewery Co Ltd, under license from NPS Pharmaceuticals Inc, are developing cinacalcet hydrochloride, the lead compound in a series of calcimimetics, for the potential treatment of primary and secondary hyperparathyroidism. Tecalcet hydrochloride was the first compound from this class to be extensively studied and most of the pharmacological data disclosed is for this compound. Cinacalcet hydrochloride was developed in an effort to improve on the poor pharmacokinetics and metabolism of tecalcet hydrochloride.
| Original language | English |
|---|---|
| Pages (from-to) | 587-592 |
| Number of pages | 6 |
| Journal | IDrugs |
| Volume | 6 |
| Issue number | 6 |
| State | Published - 1 Jun 2003 |